Its sale to Al­ler­gan was called off at the last minute. One year lat­er, a biotech co-found­ed by Hen­ri Ter­meer finds a new buy­er

Lyso­so­mal Ther­a­peu­tics went in­to JP Mor­gan 2017 with a sale all but sealed. With $100 mil­lion up­front and a $48 mil­lion cash in­fu­sion to ex­e­cute on the R&D plan, Al­ler­gan lined up an ex­clu­sive op­tion to buy the Cam­bridge, MA-based biotech once the Phase I safe­ty and proof-of-con­cept da­ta for its lead drug are in.

The team de­liv­ered the re­sults by the end of 2018, CEO Kees Been re­called, and af­ter sev­er­al months of ne­go­ti­a­tions they had shak­en hands over a June buy­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.